Northwire Canada EditionSaturday, July 18, 2026
Sign inSubscribe
Northwire
⌕
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%

Healthcare

Page 118
  1. Oct 17, 2025 · 08:27 · PHRM

    PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale

    PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale

    01
  2. Oct 17, 2025 · 07:50 · CYTO

    Cytophage Announces Non-Brokered Private Placement

    Cytophage Announces Non-Brokered Private Placement

    02
  3. Oct 17, 2025 · 07:30 · PCRX

    PharmaCorp Rx Inc. Files Final Short Form Base Shelf Prospectus

    PharmaCorp Rx Inc. Files Final Short Form Base Shelf Prospectus

    03
  4. Oct 17, 2025 · 07:00 · ZYUS

    ZYUS Life Sciences Corporation Announces Closing of Secured Loan and Amendments to Prior Secured Promissory Note

    ZYUS Life Sciences Corporation Announces Closing of Secured Loan and Amendments to Prior Secured Promissory Note

    04
  5. Oct 17, 2025 · 07:00 · XRTX

    XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

    XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

    05
  6. Oct 16, 2025 · 18:53 · METX

    ME Therapeutics licenses NRC's CD22 nanobody asset

    ME Therapeutics licenses NRC's CD22 nanobody asset

    06
  7. Oct 16, 2025 · 18:13 · PHRM

    Pharmather preparing phase 3 FDA package for ketamine

    Pharmather preparing phase 3 FDA package for ketamine

    07
  8. Oct 16, 2025 · 18:01 · MYTC

    MyndTec Inc. Completes Sixth Tranche of Non-Brokered Private Placement

    MyndTec Inc. Completes Sixth Tranche of Non-Brokered Private Placement

    08
  9. Oct 16, 2025 · 17:44 · PRN

    Profound Medical upbeat about Busch Center results

    Profound Medical upbeat about Busch Center results

    09
  10. Oct 16, 2025 · 16:58 · AGN

    Algernon Pharmaceuticals name change to Algernon Health

    Algernon Pharmaceuticals name change to Algernon Health

    10
  11. Oct 16, 2025 · 09:35 · RIZE

    Rize Oncology Announces Appointment Of Interim CEO

    Rize Oncology Announces Appointment Of Interim CEO

    11
  12. Oct 16, 2025 · 09:00 · METX

    ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

    ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

    12
  13. Oct 16, 2025 · 08:03 · PHRM

    PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease

    PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease

    13
  14. Oct 16, 2025 · 08:00 · PRN

    Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone

    Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone

    14
← Newer Older →